NCT02667873: A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors

NCT02667873
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patient with active unstable brain or leptomeningeal metastases- see trial for details
https://ClinicalTrials.gov/show/NCT02667873

Comments are closed.

Up ↑